期刊
LEUKEMIA & LYMPHOMA
卷 -, 期 -, 页码 -出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2023.2244101
关键词
Real world outcomes Extranodal NK T cell lymphoma; L-asparaginase
The staging, prognostication, and treatment of ENKTL have improved over the years with a better understanding of the disease biology. There is significant heterogeneity in the treatment strategies used worldwide. In this study, we examined the outcomes and prognostic factors of ENKTL patients treated at our center between May 2010 and December 2021. L-asparaginase based chemotherapy was administered to 84% of the patients.
The staging, prognostication, and treatment of ENKTL has evolved over the years with better understanding of the disease biology. There is significant heterogeneity in the treatment followed across the world. Literature from India have been few with small number of patients. We studied the outcomes and prognostic factors of patients with ENKTL treated between May 2010 and December 2021 at our center. A total of 78 patients diagnosed with ENKTL were treated at our center. L-asparaginase based chemotherapy was administered in 84% of the patients. Close to 2/3rd patients received SMILE chemotherapy. After a median follow-up of 30 months (18.5-41.4 months), the median relapse free survival and overall survival for the overall population was 45 months (12-118 months) and 45 months (14-118 months) respectively. By multivariate analysis, PINK score of 2-4, non-receipt of RT and non-achievement of CR were associated with poor survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据